ABSTRACT
Non-Hodgkin’s lymphomas (NHL) account for 7% of all cancers in children younger than 20 years of age (1), with about 800 new cases diagnosed each year in the United States, an incidence of approximately 1 per 100,000. The incidence of NHL rises steadily throughout life, though the agespecific incidence of various subcategories varies markedly. Overall, more than 70% of children and adolescents with NHL will survive at least 5 years. Outcome is variable depending on a number of factors, including disease subtype and extent of disease at diagnosis (2).
